07:00 , Jun 13, 2005 |  BC Week In Review  |  Clinical News

Oxford BioMedica preclinical data

In a rat model of spinal cord injury, Innurex induced nerve repair across the injury and significantly improved functional ability compared with placebo. Innurex delivers the retinoic acid receptor (RAR) beta 2 gene using the...
07:00 , Jun 7, 2004 |  BC Week In Review  |  Clinical News

Oxford BioMedica preclinical data

Innurex restored function in damaged limbs in a rat model of avulsion injury. Innurex is a lentivector delivering retinoic acid receptor (RAR) beta 2 gene, which induces neurons to produce neurite outgrowths. Data were presented...
08:00 , Dec 17, 2001 |  BC Week In Review  |  Company News

Oxford BioMedica, King’s College deal

The college made a £150,000 ($215,000) investment in OXB through the purchase of 585,000 OXB shares at 25.7p. The purchase is the college’s second investment in OXB. Under a February deal, OXB exclusively licensed the...
08:00 , Feb 12, 2001 |  BC Week In Review  |  Company News

Oxford BioMedica, King's College deal

OXB exclusively licensed retinoic acid receptor (RAR) beta 2 , a gene associated with nerve regeneration, from the college. OXB said it will combine its LentiVector gene delivery technology with the gene for spinal injury...
08:00 , Feb 12, 2001 |  BioCentury  |  Finance

Ebb & Flow

What a difference a year makes. Anticipation of this week's pending publication of the human genetic code in both Nature and Science generated about as much energy on Wall Street as the California power system....
08:00 , Feb 5, 2001 |  BC Extra  |  Company News

OXB acquires RAR beta 2 gene

Oxford BioMedica (LSE:OXB) licensed from King's College (London, U.K.) the retinoic acid receptor (RAR) beta 2 gene, which is associated with nerve regeneration. OXB intends to combine its LentiVector gene delivery technology with the gene...